Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	Health Quality Ontario (HQO)	Intermittent Catheters for Chronic Urinary Retention: A Health Technology Assessment
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81]
2019	NIHR Health Technology Assessment programme	Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: withdrawal management in adult addiction rehabilitation service centres]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: the placenta, utility of and indications for the transfer of samples to the anatomical pathology laboratory for analysis]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Determination of the SHI target population for the therapeutic indication type 2 diabetes mellitus using SHI routine data]
2019	NIHR Health Technology Assessment programme	Comprehensive geriatric assessment for frail older people in acute hospitals: the HoW-CGA mixed-methods study.
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: post-tick bite antibiotic prophylaxis to prevent Lyme disease, report in support of the knowledge transfer tools, the Québec’s national medical protocol and the collective prescription template]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Blinatumomab (ALL, paediatric patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	NIHR Health Technology Assessment programme	A workplace-based intervention to increase levels of daily physical activity: the Travel to Work cluster RCT
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: mechanisms for accessing local services]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Blinatumomab (ALL, MRD-positive patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in August 2020: pharmacological treatment of nausea in a person receiving palliative care]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis in children aged 2 to 5 years) - Benefit assessment according to §35a Social Code Book V]
2019	Agency for Healthcare Research and Quality (AHRQ)	Telehealth for acute and chronic care consultations
2019	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Gait speed as predictor of frailty]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Organization of care and services for stroke to optimize access to endovascular treatment in Quebec]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Partial breast radiotherapy for patients with early breast cancer after breast conservation surgery
2019	NIHR Health Technology Assessment programme	Development and preliminary evaluation of an intervention package to support parents of excessively crying infants
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (hepatocellular carcinoma) - Addendum to Commission A18-85]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (hepatocellular carcinoma) - Second Addendum to Commission A18-85]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Volume-outcome relationships: pancreaticoduodenectomy (Whipple procedure). Final report
2019	NIHR Health Technology Assessment programme	Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT
2019	NIHR Public Health Research (PHR) programme	A multi-centre individual-randomised controlled trial of screening and brief alcohol intervention to prevent risky drinking in young people aged 14-15 in a high school setting (SIPS JR-HIGH)
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in June 2019: unusual vaginal discharge]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment - Rapid report]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of low-dose computed tomography lung cancer screening]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (assessment of an orphan drug after exceeding the turnover limit of €1 million)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V]
2019	Agency for Healthcare Research and Quality (AHRQ)	Treatment for acute pain: an evidence map
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: portrait of the Quebec adult trauma care network: 2013 – 2016]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for stem cell transplantation - Rapid report]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Negative pressure wound therapy for wounds healing by primary intention]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brentuximab vedotin (advanced Hodgkin lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	NIHR Public Health Research (PHR) programme	Improving health, under community supervision, with the support of a Health Trainer: developing and evaluating a pilot randomised controlled trial
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	Improving the mental health of children and young people with long term conditions: linked evidence syntheses
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive (AM-RL): Annex XII – Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V brentuximab vedotin (new therapeutic indication: Hodgkin lymphoma, first line)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06]
2019	NIHR Health Technology Assessment programme	Clinical and demographic characteristics associated with delay in help-seeking behaviour in patients with Acute Coronary Syndrome
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: setting safety and conditions for success of vaginal birth after cesarean]
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Intravenous lidocaine for perioperative pain control
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Melatonin (sleep disorders in children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome) - Addendum to Commission A19-04]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: intensive outpatient services for youths with psychoactive substance use disorders]
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Levalbuterol vs albuterol for hospitalized patients
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endoscopic sleeve gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments
2019	National Institute for Health and Care Excellence (NICE)	Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. NICE diagnostics guidance 37
2019	NIHR Health Technology Assessment programme	Group cognitive behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations
2019	NIHR Health Technology Assessment programme	Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study
2019	NIHR Health Technology Assessment programme	Vitamin D supplementation to prevent acute respiratory infection: individual patient data meta-analysis of randomised controlled trials
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Triple-lumen peripherally-inserted central catheters
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for chronic inflammatory demyelinating polyneuropathy
2019	National Institute for Health and Care Excellence (NICE)	Rapid tests for group A streptococcal infections in people with a sore throat. NICE diagnostics guidance 38
2019	NIHR Health Technology Assessment programme	Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Tip positioning of short-term central venous catheters
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis. NICE diagnostics guidance 36
2019	NIHR Health Technology Assessment programme	Fuelling health equity? The impact of the Winter Fuel Payment on the health of UK households
2019	NIHR Health Technology Assessment programme	Minimally invasive autopsy for fetuses and children based on a combination of post-mortem MRI and endoscopic autopsy examination; feasibility study
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Timing of valve replacement for patients with infective endocarditis and intracranial embolism
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care. NICE diagnostics guidance 35
2019	NIHR Public Health Research (PHR) programme	How can interventions integrating health and academic education in schools help prevent substance misuse and violence, and reduce health inequalities among young people? Systematic review and evidence synthesis
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Participation in athletics by persons with thoracic aortic disease
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	A behaviour change package to prevent hand dermatitis in nurses working in health care: the SCIN cluster RCT
2019	NIHR Health Services and Delivery Research programme	Evaluating the ten year impact of the Productive Ward at the clinical microsystem level in English acute trusts
2019	Health Quality Ontario (HQO)	Compression Stockings for the Prevention of Venous Leg Ulcer Recurrence: A Health Technology Assessment
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Postoperative chlorhexidine bathing to reduce surgical site infections among patients undergoing cardiac surgery
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Caplacizumab (New Therapeutic Indication: Acquired Thrombotic Thrombocytopenic Purpura, 12 to < 18 Years)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ezetimibe for the prevention of cardiovascular events - Rapid report]
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: dose banding and dose rounding of antineoplastic agents]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Voretigene neparvovec (vision loss due to inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Adelaide Health Technology Assessment (AHTA)	Heritable Mutations associated with Familial Hypercholesterolaemia
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Radium-223 dichloride (mCRPC) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Addendum to Commission A19-09]
2019	NIHR Public Health Research (PHR) programme	Mass media for public health messages
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12]
2019	NIHR Health Technology Assessment programme	E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for sickle cell disease]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glycerol phenylbutyrate (New Therapeutic Indication: Urea cycle disorders in infants aged 0 to < 2 months)]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	European Network for Health Technology Assessment (EUnetHTA)	Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endoscopic sleeve gastroplasty (ESG) for the treatment of patients with Class I and II obesity who have failed first-line treatments
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V]
2019	European Network for Health Technology Assessment (EUnetHTA)	Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ixazomib]